🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A Phase 3 Biomarker Validation of GALAD for the Detection of HCC in Cirrhosis Gastroenterology doi.org/10.1053/j.gast… 🔎1,558 pts, 109 HCCs 👉GALAD better than AFP to detect HCC within 12 months before diagnosis ESMO - Eur. Oncology EASL Education ILCA

#Y90 Radiation Segmentectomy has expanded access to curative intent therapy for many patients with early stage #HCC who are not candidates for resection or thermal ablation. 🧩 sciencedirect.com/science/articl…

💉Adding Tiraglumab to Atezo-Beva in 1L of HCC MORPHEUS-Liver The Lancet Oncology ➡️ anti-TIGIT, phase 1b–2 ✅ORR: 43% vs. 11% ✅Serious adverse events: 53% vs. 56% ✅mPFS: 12.3 vs. 4.2 mo ✅mOS: 28.9 vs. 15.1 mo 👉doi.org/10.1016/S1470-… OncoAlert Arndt Vogel Lorenza Rimassa

Efficacy of resection for initially unresectable HCC after atezo/ beva #ASCOGI25 🔎 RACB phs 2, 55 pts, MWS/EHS in 76% 👉ORR 13% 👉resection rate 48% 👉conversion surgery is feasible after atezo+bev 🧐 Mutlidiscplinary discussion is key in HCC: Downstaging to curative treatments

Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy JNCI doi.org/10.1093/jnci/d… 🔎🇺🇸RWD, >200pts 👉HAI with CTx can offer long-term durable disease control: mOS >20mo ESMO - Eur. Oncology EASL Education ILCA

📣 Updated ESMO #ClinicalPracticeGuideline on #HepatocellularCarcinoma includes new treatment strategies in early- and intermediate-stage disease and evolving options for systemic therapy. #HCC #GastrointestinalCancers #ESMOGuidelines 🔗 ow.ly/hrhH50V2GiU

🔥off the press: Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Annals of Oncology doi.org/10.1016/j.anno… 👉get the lastest update on HCC management 👉Multiple options > MDT is key ESMO - Eur. Oncology EASL Education ILCA #livertwitter

❗️First-line chemotherapy with selective internal radiation therapy for intrahepatic #cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort 🔓#OpenAccess at👉jhep-reports.eu/article/S2589-… #LiverTwitter

🟪NEW Article in press❕ Serum FGF21 as predictor of response to atezolizumab and bevacizumab in #HCC 🔓#OpenAccess at 👉jhep-reports.eu/article/S2589-… #LiverTwitter

Liver decompensation in patients with hepatocellular carcinoma treated with Atezo + Beva 🔎 real-life study CGH doi.org/10.1016/j.cgh.… 👉Liver decompensation in 28% of CP A & and 51% of CP B pts 👉💊may be restarted after decompensation ESMO - Eur. Oncology EASL Education ILCA

Congratulations to Dr Yen-I Chen and all of the faculty and nurses for organizing an excellent live endoscopy course Joint CDDW™-CLM Conference | #CDDWCLM2025 Centre universitaire de santé McGill Talat Bessissow Amazing work!

📋Anti (TIGIT + PDL1 + VEGF) for advanced HCC NatureRevClinOncol ✅ A news&comment from Bruno Sangro and Josepmaria Argemi on MORPHEUS-Liver ➡️Tiragolumab-atezo-beva 🔄HCC treatment is quickly evolving 👉doi.org/10.1038/s41571… OncoAlert #cancer #oncology #liver #MedX

Congratulations to our very own Dr. Alan Barkun for this well deserved award! A mentor and inspiration to so many GI’s across the globe. Thank you Dr. Barkun for your dedication to improving clinical GI care. Centre universitaire de santé McGill Alan Barkun

🆕 ‘Health in Canada: a pivotal political moment’ Read the latest Lancet Editorial: hubs.li/Q03bSTVg0 📖 Full issue: hubs.li/Q03bSKFk0

We are proud to present our first ever Clinical Achievement Award to Dr. Alan Barkun! Thank you for your remarkable contributions to clinical GI. #CAGawards2025

Original Article Corticosteroids in severe alcohol-associated hepatitis? Not so fast: A systematic review of randomized controlled trials Shi, Pungwe et al. #LiverX tinyurl.com/mzzk8uar

📢 LEAP-012 publication snapshot 📢 Key insights from the Phase 3 LEAP-012 study ➡️Lenvatinib + pembrolizumab + TACE versus double placebo + TACE for patients with intermediate HCC 📺Prof. Arndt Vogel puts the results into clinical context Get the infographic:

EORTC consensus recommendations on the optimal management of CRC liver metastases Oncology Advance doi.org/10.1016/j.ctrv… 👉43 experts, 12 🇪🇺 countries, 34 recommendations, 2 consensus statements 🧐multiple options, multidisciplinary care is key ESMO - Eur. Oncology

The FDA has approved nivolumab + ipilimumab for patients with unresectable or metastatic #HCC 👏 fda.gov/drugs/resource…

Patients with #PSC face transplant delays due to the limitations of the MELD score. Authors report the development of a machine learning model (RSF) that outperforms MELD in predicting waitlist outcomes. #LiverTransplantation #TXPforAll tinyurl.com/2us6wsr9